IMS Annual Meeting 2022: High Risk MM
The 19th International Myeloma Society Annual Meeting hosted a session dedicated to High-Risk Myeloma for its attendance from around the...
Volume 2, Issue 2
Meeting Updates
IMS Annual Meeting 2022: Relapsed MM
The session on Relapsed MM, chaired by Dr. Kenneth Anderson, began with a presentation by Dr. Nizar Bahlis focusing on...
IMS Annual Meeting 2022: Induction for Newly Diagnosed Myeloma
The Induction for Newly Diagnosed Myeloma session, chaired by Dr. Philippe Moreau, covered a wide range of topics, starting with...
IMS Annual Meeting 2022: Immune Reconstitution and Vaccination
Immune Reconstitution and Vaccination session was chaired by Dr. Noopur Raje. Dr. Paola Neri provided an overview on the immune status...
IMS Annual Meeting 2022: Disease Monitoring
Professor Jesus San Miguel chaired the Disease Monitoring session and discussed the most important data in the field. Speakers and...
T-cell Redirecting Therapies for Multiple Myeloma Treatment
Triple-class refractory MM patients have a poor outcome and have an unmet medical need for new effective therapies. The LocoMMotion...
Treatment of new diagnosed Myeloma patients
Significant updates were presented in ASCO and EHA for the treatment of patients newly diagnosed disease. In the late breaking...